Immunohistochemical Expression of Ki-67 and E.cadherin in Breast Cancer among Sudanese patients

Abstract

This is a descriptive cross sectional hospital based retrospective study, the study was conducted at Radiation and isotopes center -Khartoum ( RICK) ,Patient identification data and other information were obtained from patient’s file during the period from February to October 2018, aimed to assess the expression of ki67 and E.cadherin in breast cancer in Sudanese patients using immunohistochemistry (Dako), immunohistochemistry results and Patients information were obtained from department medical records of cases diagnosed as breast cancer that had their samples processed in the department of Histopathology of Radiation and isotopes center -Khartoum ( RICK). Eighty cases with relevant histopathologic and clinical information sampled from February to October (2018) breast cancer results were studied. According to markers results breast cancer were selected and classified into two categories, 40(50%) triple negative and 40(50%) non triple negative breast cancer. The patient’s age were ranged between 20- 80 years old with mean age of 46 years. According to histopathogical diagnosis the study showed that 66 (82.5%) were invasive ductal carcinoma ,7 (8.8%) were invasive lobular carcinoma, 2 (2.2%) were invasive mammary carcinoma, 2 (2.5%) were metaplastic carcinoma, 2 (2.5%) were papillary carcinoma and 1 (1.2%) was mucinous carcinoma. The tumor grade of study sample revealed that 4 (5.0%) samples were grade I , 30 (37.5%) samples were grade II and 47 (57.5%) samples were grade III . ki67 index were more than 20 representing 48 (60%) and the remaining 32 (40%) were less/equal 20 with significant correlation with tumar types. E.cadherin was positive in 68 (80%) of cases and negative in 12 (20%) of other. The study concluded there is association between ki67 expression and both triple negative and non triple negative breast cancer, no association between ki67 expression and tumor grade, while these is no association between E.cadherin and triple negative and non triple negative breast cancer, as well as tumor grade.